Never invest in any stock unless you can afford to lose your entire investment. Omnivance Advisors is typically compensated by client companies with restricted shares of stock which may cause a conflict in interest.

The information and content contained within this website or disseminated by either Omnivance Advisors and/or Daniel Wong, its Owner (collectively hereinafter referred to as “OmniVance”) in any fashion, including email and social media sites such as Twitter and Linkedin, is for informational purposes only and is not an offer to sell securities or a solicitation of offers to purchase securities and should not be construed to be investment advice.  OmniVance is not a broker-dealer, registered investment adviser, financial analyst, investment broker, financial adviser, or any sort of professional that would be deemed as an individual someone would rely upon for investment advice, and OmniVance shall not be held liable for any investment or trading losses one may incur by using the information contained within this website or disseminated by OmniVance. You should not construe any of the material contained within this website or disseminated by OmniVance  as business, financial, investment, trading, legal, regulatory, tax, or accounting advice, and you should consult your business adviser, attorney, and tax and accounting advisers concerning any contemplated transactions.

Information on this website or disseminated by OmniVance, including but not limited to any client company press releases, investor presentations, corporate overviews, newsletters, analysts’ reports, etc.  is obtained from OmniVance’s client companies, public filings, or publicly available sources deemed to be reliable; however, OmniVance takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete and consequently it should not be relied upon as such. The information is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject OmniVance to any registration requirement within such jurisdiction or country. OmniVance reserves the right to add, modify or delete any information on this website at any time.

In general, given the developmental stage of OmniVance ‘s client companies, as well as the lack of liquidity in shares of client companies, investing in such shares is highly speculative and carries a high degree of risk. Investing in microcap stocks is very risky due to extreme volatility. An investor in such securities should be prepared and able to bear loss of his or her entire investment and should perform extensive independent due diligence prior to any purchase or sale of securities.

The information contained in this website or disseminated by OmniVance may contain “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated including (i) all of the risks and uncertainties associated with developmental businesses; (ii) any particular Clients’ possible lack of capital and their ability to obtain capital as needed; (iii) intense competition for products and services within the Clients’ industry; (iv) the timely development and market acceptance of the Clients’ products, services or technologies; and (v) the successful integration of any acquisitions and lines of business.  All information contained in this website or disseminated by OmniVance that may include forward-looking statements pertaining to future anticipated projected plans, performance and developments; and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995.  There are a number of important factors that could cause actual events or actual results of the client companies to differ materially from these indicated by such forward-looking statements, many of which can be found in the company clients’ SEC filings at OmniVance and its company clients undertake no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of information disseminated by OmniVance.

OmniVance has been retained by its clients companies as a consultant in the investor relations field and for related services, and as such, the clients companies have compensated OmniVance by issuing restricted shares of the client company’s common stock and/or making cash payments. OmniVance will profit from its investor relations activities for its client companies.  From time to time, OmniVance and its officers and employees will own or acquire additional securities issued by its client companies and/or will dispose of securities issued by its client companies that they hold.  OmniVance does not undertake any obligation to provide any information on purchases and/or sales of securities issued by its client companies.

Section 17(b) Disclosures


Updated November 7, 2017:

To be in compliance with Rule 17(b) as contained in the Securities Act of 1933, as amended, Investor Town Hall, LLC, or its affiliates (which includes Omnivance Advisors) must provide full disclosure of all compensation received for investor relations efforts on behalf of a publicly traded issuer.

This information must include the following:
• Type of compensation (securities or cash) received;
• If the compensation is in securities, whether the securities are restricted or unrestricted;
• Amount of securities or cash paid;
• Source of compensation (directly and indirectly) and if compensated by a third party shareholder or corporate entity, the shareholder or control persons of the entity must be identified by his or her individual name; and
• If a corporate entity is the publisher of the information, the control persons of the corporate entity must be disclosed.




KSIX Media Holdings, Inc. (KSIX)
Currently in a six (6) month contract for 45,000 restricted shares and two thousand dollars ($2,000) per month beginning 11/1/2017 & ending 5/1/2017

Pressure BioSciences, Inc. (PBIO)
Currently in a month to month contract at three thousand dollars ($3,000) per month.

Fernhill Corp. (FERN)

Currently in a six (6) month contract for five million (5,000,000) restricted shares and one thousand dollars ($1,000) per month beginning 5/16/2017 & ending 11/16/2017


Opiant Pharmaceuticals, Inc. (OPNT)

Currently in a month to month contract at three thousand dollars ($3,000) per month.